Pharmacy and Therapeutics Committee

Transcription

1 Michigan Department of Health and Human Services Pharmacy and Therapeutics Committee December 13, 2016 Minutes Attendees: Dr. Tutag Lehr, Andrew Mac, James Miller, Brian Peltz, Dr. Anthony Ognjan, Dr. Steve Hadesman (by phone), Dr. Brad Uren, Dr. Jayne Courts, Dr. Venkat Rao, Dr. Eggleston. A quorum was met. The MDHHS P & T committee was called to order at 6:05 pm by the chair, Dr. Vicki Tutag Lehr. The agenda was reviewed and accepted. Introductions were made and quorum established. Conflict of interest statement was reviewed. Annual attestations were signed. None of the members had COI to report. Review of the June 14, 2016 and September 13, 2016 meeting minutes were reviewed and accepted. P & T Business: The Committee was provided Policy Updates, Legislative Updates, Pipeline Drugs and New Indications, an update on the revamping of MAPS, the DUR update and general clinical updates. New Drug Review: The committee reviewed the following new drugs and approved that the following new agents reviewed be added to the formulary as non-preferred as follows:

2 1. Bevespi Aerosphere (glycopyrrolate and formoterol) [PDL class: COPD: Beta Adrenergic/Anticholinergic Combinations; nonpreferred] 2. Migranow (sumatriptan tablets with a camphor/menthol gel) [PDL class: Serotonin Receptor Agonists: Triptans; non-preferred] 3. Xiidra (lifitegrast) 5% ophthalmic solution - [Not a PDL class, add to the MPPL--?PA] 4. Xtampza ER (oxycodone extended-release) - [PDL class: Narcotics, Longacting; non-preferred] 5. Zinbryta (daclizumab subcutaneous injection) - [PDL class: Multiple Sclerosis Agents: non-preferred] The review of the following new agent was tabled pending further evaluation of the topical NSAID subclass. 1. Vopac MDS (diclofenac) [PDL class: NSAIDs; tabled] Preferred Drug List Classes: A Review of the following Preferred Drug Classes was performed and the following actions were taken. Analgesics: 1. Narcotics: Long-acting 2. Narcotics: Short- and Intermediate-acting

3 a. Move oxycodone oral syringes to non-preferred. 3. Narcotics: Transdermal 4. NSAIDs: COX-II Inhibitors 5. NSAIDs a. Move fenoprofen to non-preferred b. Move flurbiprofen to non-preferred Central Nervous System Agents 1. Alzheimer s Dementia 2. Anti-Anxiety - General 3. Drugs for ADHD Stimulants a. Move Ritalin LA (all strengths except 10mg) to non-preferred. b. Move methylphenidate LA (all strengths except 10mg) to preferred. 4. Drugs for ADHD Non-stimulants 5. Fibromyalgia Agents 6. Multiple Sclerosis Agents: a. Move Extavia (interferon beta-1b) kit and vial to non-preferred 7. Non-Ergot Dopamine Receptor Agonsists (Anti-Parkinson s Agents) 8. Sedative Hyponotics: Nona. No change to the current classification of drug products

4 9. Serotonin Receptor Agonists (Antimigraine Agents, Triptans) a. Move Maxalt MLT (rizatriptan) to non-preferred b. Move Relpax (eletriptan) to preferred. Dermatological Agents: 1. Topical Immunomodulators 2. Topical Steroids Low Potency 3. Topical Steroids Medium Potency 4. Topical Steroids High Potency a. Move fluocinonide cream, ointment and gel to non-preferred b. Move betamethasone valerate cream, ointment and lotion to preferred. 5. Topical Steroids Very High Potency Public Comments: 1. Birgit Amann, MD, Psychiatrist & Marcus DeGraw, MD, Pediatrician: Rhodes Pharmaceuticals: Aptensio XR 2. Rick Detloff, PharmD, Pfizer: Eliquis 3. Ashley Polce, PharmD, Abbvie: Zinbryta 4. Ndidi Yaucher, PharmD, MBA, Novartis: Entresto 5. Paul Miner, PharmD, Gilead: Hepatitis C - passed 6. Mary Pat Petrillo, PharmD, Johnson & Johnson: Invokamet XR and Stelara 7. Jeff Martin, PharmD, MPA, Amgen: Enbrel

5 8. Sharad Rastogi, MD, MBA, Shire Medical Affairs Group: Xiidra The meeting was adjourned at 8:32 PM Next Meeting: Tuesday, March 14, 2016 Location: Kellogg Center